Mario Javier Pineda

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Robert J. Morgan, Deborah K. Armstrong, Ronald D. Alvarez et al. · Journal of the National Comprehensive Cancer Network · 2016 · 323 citations · Full text

Medicine, Gynecology, Oncology +17

Safety and dose modification for patients receiving niraparib

Jonathan S. Berek, Ursula A. Matulonis, Ulla Peen et al. · Annals of Oncology · 2018 · 187 citations

Pharmacy, Oncology, Pharmacology +17

Role of two upstream open reading frames in the translational control of oncogene mdm2

Cheryl Y. Brown, Gregory J. Mize, Mario Javier Pineda et al. · Oncogene · 1999 · 111 citations

Life Sciences, Molecular Biology, Oncology +14

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

Michel Fabbro, Kathleen N. Moore, Anne Dørum et al. · Gynecologic Oncology · 2019 · 49 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A TRIM5α-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry

Mario Javier Pineda, Brannon R. Orton, Julie Overbaugh · Virology · 2007 · 31 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16